GURU.Markets stock price, segment price, and overall market index valuation
The company's share price KOD
Kodiak Sciences is a biotech company developing drugs to treat retinal diseases. Its stock price reflects the binary risks of clinical trials. The chart is a story of high hopes and sharp declines following the publication of research data.
Share prices of companies in the market segment - Pharma eyes
Kodiak Sciences is a biopharmaceutical company specializing in the development of innovative treatments for retinal diseases. We classify it in the Pharmaceuticals (Eye) segment. The chart below reflects the overall performance of this highly specialized yet important healthcare sector.
Broad Market Index - GURU.Markets
Kodiak Sciences is a biopharmaceutical company developing long-acting treatments for retinal diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Kodiak's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
KOD - Daily change in the company's share price KOD
Kodiak Sciences, a biopharmaceutical company, has volatility measured by change_co. It reflects its sensitivity to the results of clinical trials of its eye disease treatments. This metric is important for biotech sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Kodiak Sciences Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with KOD, which focuses on eye disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Kodiak is a biopharmaceutical company specializing in eye care. Ophthalmology is a highly specialized and competitive field. The chart below shows the volatility in this sector, allowing you to gauge how Kodiak shares react to industry news.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization KOD
Kodiak Sciences' year-over-year performance epitomizes biotech risk. Its market cap over 12 months can fluctuate dramatically depending on the results of clinical trials of its retinal disease drug. It's a binary event: success promises a huge market, while failure means a loss of the company's core value.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Kodiak Sciences Inc. is a clinical-stage biotech developing drugs for the treatment of retinal diseases. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this vast but competitive field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kodiak Sciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials for eye diseases. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization KOD
Kodiak Sciences, a biopharmaceutical company, has a speculative market cap. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its eye disease treatments, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Kodiak Sciences is a biopharmaceutical company developing innovative treatments for retinal diseases that may require less frequent injections than existing therapies. The graph below illustrates the overall dynamics in the ophthalmic pharmaceutical sector, where patient convenience is a key success factor.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks, especially in a complex field like ophthalmology, often take on a life of their own, reacting to trial news. The chart below shows general market trends. Is Kodiak Sciences following this trend, or are its R&D activities creating a unique story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization KOD
Kodiak Sciences, a biopharmaceutical company developing drugs to treat retinal diseases, is extremely sensitive to news. Its weekly stock price reflects the results of key clinical trials.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Kodiak Sciences operates in the highly competitive ophthalmology sector, where investor sentiment drives global sentiment. The success or failure of a major blockbuster drug (such as Eylea) influences expectations for all companies in the niche. The chart below shows how KOD fares within this competitive landscape compared to other developers.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Kodiak Sciences, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how KOD shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
KOD - Market capitalization of the company KOD
Kodiak Sciences' stock chart is a focused bet on treating retinal diseases such as age-related macular degeneration. This biotech's market capitalization is entirely dependent on the success of its innovative drug. Its sharp rises and falls are a direct market reaction to the results of key clinical trials.
KOD - Share of the company's market capitalization KOD within the market segment - Pharma eyes
Kodiak Sciences is a clinical-stage biopharmaceutical company developing drugs for the treatment of retinal diseases. Its market capitalization in its niche segment reflects high expectations for its lead drug. The chart below shows extreme volatility associated with key clinical trial results.
Market capitalization of the market segment - Pharma eyes
Kodiak Sciences develops long-acting medications for the treatment of retinal diseases. The chart below shows the market capitalization of the ophthalmology pharmaceutical sector. This represents a market seeking more convenient and effective treatments for age-related eye diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Kodiak Sciences is a biopharmaceutical company developing long-acting medications for the treatment of retinal diseases. The company's market capitalization is based on its ability to create a drug that requires less frequent administration than existing ones. Its market share is driven by the weight of its innovations aimed at improving convenience for patients with chronic eye diseases.
Book value capitalization of the company, segment and market as a whole
KOD - Book value capitalization of the company KOD
Kodiak Sciences is built on a bioscience platform. The company, which develops drugs for retinal diseases, derives its book value from patents for its ABC Platform technology and cash flow for highly expensive clinical trials. The chart below shows how the company is deploying its capital in its quest to achieve breakthroughs in ophthalmology.
KOD - Share of the company's book capitalization KOD within the market segment - Pharma eyes
Kodiak Sciences, a biopharmaceutical company, focuses on treating retinal diseases. Its laboratories are its primary tangible asset. The S_BCap_Seg graph shows its share of the physical R&D infrastructure in the ophthalmology sector.
Market segment balance sheet capitalization - Pharma eyes
Biotechnology is a world of contrasts. The graph shows the massive manufacturing plants of pharmaceutical giants. Kodiak Sciences, as a development company, has a more streamlined model. Its value lies in its intellectual property rights to eye treatments, not in its scale of production.
Book value of all companies included in the broad market index - GURU.Markets
Kodiak Sciences develops innovative drugs for the treatment of retinal diseases. The company's assets are not massive factories, but rather a cutting-edge scientific platform for creating long-acting treatments. The chart below shows the material resources dedicated to the fight against blindness.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - KOD
Kodiak Sciences' balance sheet is made up of cash in its accounts and the value of its scientific platform. The market, however, isn't measuring this, but rather the hope that its eye disease drug will become a blockbuster. The chart shows how much the stake in this single key drug exceeds all its tangible assets.
Market to book capitalization ratio in a market segment - Pharma eyes
Kodiak Sciences Inc. is a biotech company developing drugs to treat retinal diseases. Its value is entirely dependent on the success of its clinical programs. This chart clearly shows how its market valuation is a bet on future drugs and is significantly disconnected from its current assets.
Market to book capitalization ratio for the market as a whole
Kodiak Sciences is a biopharmaceutical company focused on treating retinal diseases. Its value depends almost entirely on the success of its lead drug in clinical trials. This chart is a classic example of biotech startup valuation, where investors are betting on a future blockbuster rather than current revenue or balance sheet assets.
Debts of the company, segment and market as a whole
KOD - Company debts KOD
Kodiak Sciences, a biotech focused on treating retinal diseases, is using raised capital to conduct large-scale and expensive clinical trials. This chart shows how the company is spending hundreds of millions of dollars in hopes of creating a best-in-class drug and capturing the vast ophthalmology market.
Market segment debts - Pharma eyes
Kodiak Sciences is a clinical-stage biotech company focused on treating retinal diseases. Developing ophthalmic drugs is a lengthy and expensive process. This chart shows how the company's debt burden reflects its need to fund large-scale clinical trials to bring its innovative drugs to a competitive market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio KOD
Kodiak Sciences is a biopharmaceutical company developing drugs for retinal diseases. It's a huge market, but competition is fierce. This chart shows how the company is using debt to finance its very expensive and lengthy clinical trials in hopes of creating a blockbuster.
Market segment debt to market segment book capitalization - Pharma eyes
Kodiak Sciences, a clinical-stage biotech developing long-acting drugs for retinal diseases, compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company is funding its long-term and expensive research, aiming to change the standard of care.
Debt to book value of all companies in the market
Kodiak Sciences Inc. is a biopharmaceutical company developing drugs to treat retinal diseases. Clinical trials in ophthalmology are lengthy and expensive. This chart of total market debt helps understand the financial environment in which Kodiak is raising capital to fund its ambitious programs aimed at improving the vision of millions of people.
P/E of the company, segment and market as a whole
P/E - KOD
This figure for Kodiak Sciences, a clinical-stage biopharmaceutical company focused on treating retinal diseases, illustrates investors' faith in its science. There is no profit. The chart reflects investors' expectations for the success of its innovative approach to creating long-acting drugs for the vast ophthalmology market.
P/E of the market segment - Pharma eyes
Kodiak Sciences is a biopharmaceutical company developing treatments for retinal diseases. Its platform is aimed at creating longer-acting drugs that require less frequent injections. This chart illustrates the average valuation in the ophthalmic pharmaceutical sector, where investors value innovations that improve patients' quality of life.
P/E of the market as a whole
Kodiak Sciences is a biopharmaceutical company focused on treating retinal diseases. Its valuation is heavily dependent on the results of clinical trials of its long-acting drugs. This chart illustrates the overall sentiment in the biotech sector. Comparing it with it reveals how Kodiak's valuation is detached from market realities and relies solely on hopes for a scientific breakthrough.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company KOD
This chart for Kodiak Sciences, a biopharmaceutical company focused on treating retinal diseases, shows market expectations for its pipeline drugs. It reflects investor confidence that its innovative drugs will capture a significant share of the ophthalmology market.
%20P%2FE%20KOD&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-KOD&v=1772576645325 "Chart of the company's future (projected) P/E KOD")
Future (projected) P/E of the market segment - Pharma eyes
Kodiak Sciences Inc. is a biotech company developing drugs to treat retinal diseases. This chart shows average expectations for the biotech sector. KOD's position may indicate the level of investor confidence in its antibody platform and the potential of its drug candidates to treat leading causes of blindness.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772576645399 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Kodiak Sciences develops drugs to treat retinal diseases. This is a highly specialized area of biotechnology. The company's success depends on the results of clinical trials, not on general economic cycles. However, sentiment on this chart influences the cost of capital for R&D.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772576645543 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit KOD
Kodiak Sciences Inc. is a biopharmaceutical company focused on developing treatments for retinal diseases. This chart reflects the long and capital-intensive drug development process. It shows significant investment in clinical trials, with future profits dependent on the success and commercialization of their innovative vision products.
Profit of companies in the market segment - Pharma eyes
Kodiak Sciences Inc. is a biotech company developing drugs to treat retinal diseases. Profitability in the ophthalmology sector, as this chart shows, is driven by an aging population and the prevalence of diseases such as diabetes. For KOD, success depends on developing drugs that are more durable and effective than existing treatments.
Overall market profit
Kodiak Sciences, a biopharmaceutical company developing drugs to treat retinal diseases, operates in a market driven by medical needs and innovation. Demand for treatments for age-related eye diseases is constant and unaffected by economic cycles, as shown in this graph. The company's success is determined by the results of clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company KOD
Kodiak Sciences develops innovative drugs for the treatment of retinal diseases. This chart reflects analysts' forecasts for future profits, which are based on the success of its long-acting drugs in clinical trials. This is an assessment of its potential to disrupt the ophthalmology market.
%20profit%20of%20the%20company%20KOD&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-KOD&v=1772576645893 "Graph of future (projected) profit of the company KOD")
Future (predicted) profit of companies in the market segment - Pharma eyes
Kodiak Sciences Inc. is a biopharmaceutical company specializing in the development of treatments for retinal diseases. Its goal is to create longer-acting drugs that require less frequent injections. This chart shows the revenue forecast for the ophthalmology pharmaceutical sector, reflecting expected demand for innovative treatments for age-related eye diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772576645976 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Kodiak Sciences is a biopharmaceutical company specializing in the treatment of retinal diseases. Its success depends on the results of clinical trials and regulatory approval. The overall economic outlook has little impact on demand for its future products, but it does significantly influence investor sentiment and the availability of capital to fund expensive R&D.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772576646016 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - KOD
Kodiak Sciences is a biopharmaceutical company developing innovative treatments for retinal diseases. Its goal is to create drugs that require less frequent injections. While in clinical development, it may not generate revenue. The chart reflects investor assessments of its scientific potential and prospects in the vast ophthalmology market.
P/S market segment - Pharma eyes
Kodiak Sciences develops innovative treatments for retinal diseases, aiming to create longer-acting drugs. The chart shows the average revenue estimate for the biotech sector, allowing us to assess how much investor expectations for its research exceed the pharmaceutical industry average.
P/S of the market as a whole
Kodiak Sciences Inc. is a biopharmaceutical company developing long-acting treatments for retinal diseases. Its goal is to reduce the frequency of injections for patients. A graph of average market revenue estimates shows that investors are betting on its technology to change the standard of care in ophthalmology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company KOD
Kodiak Sciences is a biopharmaceutical company specializing in the treatment of retinal diseases. The chart reflects an assessment of its scientific potential. The value is determined based on projected future revenues from its innovative, long-acting drugs, which have the potential to change the standard of eye disease treatment.
%20P%2FS%20KOD&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-KOD&v=1772576646212 "The graph of the company's future (projected) P/S KOD")
Future (projected) P/S of the market segment - Pharma eyes
Kodiak Sciences Inc. is a biopharmaceutical company developing drugs to treat retinal diseases. This chart shows the average future sales estimates for ophthalmology companies. It provides an opportunity to assess how investors view the potential of Kodiak's ABC platform and its lead drug compared to existing and developing therapies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772576646262 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Kodiak Sciences Inc. is a biopharmaceutical company specializing in the treatment of retinal diseases. This is a huge market, but KOD's success depends on the results of clinical trials for its key drug. This indicator of overall revenue expectations is of little importance to the company. Scientific data and regulatory approval will decide everything.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772576646479 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales KOD
Kodiak Sciences is a clinical-stage biopharmaceutical company specializing in the treatment of retinal diseases. Revenue, if present in this chart, likely comes from payments from development partners. These funds allow the company to advance its innovative drugs through costly clinical trials.
Sales of companies in the market segment - Pharma eyes
Kodiak Sciences Inc. is a biopharmaceutical company developing innovative treatments for retinal diseases. Their ABC Platform enables the creation of long-acting medications, potentially reducing the frequency of injections for patients. This chart shows the total revenue in the sector, reflecting the need for new and more convenient treatments for common eye diseases.
Overall market sales
Kodiak Sciences Inc. is a biopharmaceutical company specializing in the treatment of retinal diseases. This chart illustrates the state of the economy, but for KOD, other factors are important: demographics and innovation. An aging population is leading to an increase in eye diseases, creating a huge market for the new, more effective and convenient treatments the company is developing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company KOD
Kodiak Sciences is a biopharmaceutical company developing innovative treatments for retinal diseases. Its future depends on the success of clinical trials and the potential of its drugs, which require less frequent injections. This timeline reflects expectations for the commercialization of breakthrough treatments for blindness.
%20sales%20of%20the%20company%20KOD&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-KOD&v=1772576646720 "Schedule of future (projected) sales of the company KOD")
Future (projected) sales of companies in the market segment - Pharma eyes
Kodiak Sciences is a clinical-stage biotechnology company developing innovative treatments for retinal diseases. Its goal is to create drugs that require less frequent injections. The graph shows forecasts for the ophthalmology pharmaceutical sector. Kodiak's success could significantly improve the quality of life for millions of patients.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772576646773 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Kodiak Sciences is a biopharmaceutical company developing drugs for the treatment of retinal diseases. Its prospects depend on the success of clinical trials and future demand for its medications. This schedule, reflecting overall economic forecasts, affects the long-term solvency of healthcare systems that will be required to pay for new, effective treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772576646885 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality KOD
Kodiak Sciences is a biopharmaceutical company focused on treating retinal diseases. Its financial performance reflects its significant investment in clinical research to develop next-generation drugs. This chart shows the company's path from scientific development to potential commercialization and profitability.
Market segment marginality - Pharma eyes
Kodiak Sciences is a biopharmaceutical company developing long-acting treatments for retinal diseases. This chart shows the average profitability in the pharmaceutical industry. Its innovative platform, which reduces the frequency of injections for patients, gives the company the potential to capture a large market share and achieve high profitability.
Market marginality as a whole
Kodiak Sciences Inc. is a biopharmaceutical company specializing in the treatment of retinal diseases. It is in clinical development, which means high research expenses. This total profitability chart clearly demonstrates that the path to developing a new drug is an investment marathon, not the sprint for quick margins typical in other industries.
Employees in the company, segment and market as a whole
Number of employees in the company KOD
Kodiak Sciences is a biotech company focused on retinal diseases. The size of its team directly reflects the activity of its clinical development. Conducting complex, global late-stage trials requires a large team, making this chart an indicator of the scale of its research.
Share of the company's employees KOD within the market segment - Pharma eyes
Kodiak Sciences is developing a new generation of drugs for the treatment of retinal diseases. Its goal is to create medications that require less frequent injections than existing standards. This chart shows the percentage of scientists Kodiak attracts in the narrow field of ophthalmology. It reflects its scientific focus and the concentration of talent working to solve this important problem.
Number of employees in the market segment - Pharma eyes
Kodiak Sciences Inc. is a biopharmaceutical company focused on developing innovative treatments for retinal diseases. The growth of its clinical and research team, visible in the graph, is a key indicator of progress. This increase in staffing indicates that its drug candidates are successfully advancing through clinical trials.
Number of employees in the market as a whole
Kodiak Sciences Inc. develops drugs to treat retinal diseases. Its business is driven by the demographics of the aging population and the success of its clinical programs, rather than by the overall employment shown in this chart. The need for effective treatments for age-related eye diseases will only grow.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company KOD (KOD)
Kodiak Sciences Inc. is a biotech company focused on treating eye diseases. Its market capitalization reflects investors' bets on the success of its scientific research. This chart clearly demonstrates how the market values intellectual capital in biotech. The company's entire value is attributed to its small team of scientists.
%20of%20the%20company%20KOD%20(KOD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-KOD-KOD&v=1772576647341 "Chart of market capitalization per employee (in thousands of dollars) of the company KOD (KOD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Kodiak Sciences Inc. is a biotech company developing drugs to treat retinal diseases. Its market capitalization is based on the potential for long-term clinical trials conducted by a small team of scientists. This chart shows how the market values their scientific potential per team member.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772576647427 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Kodiak Sciences is a clinical-stage biopharmaceutical company specializing in the treatment of retinal diseases. The chart illustrates its scientific potential. The high market capitalization per employee reflects the investors' belief that their innovative drugs will capture a significant share of the large ophthalmology market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772576647513 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company KOD (KOD)
Kodiak Sciences is a biopharmaceutical company specializing in the treatment of retinal diseases, a highly competitive field. This chart shows their R&D productivity. It measures how much capital is invested (or "burned") per scientist in the pursuit of a best-in-class drug to treat blindness.
%20Chart%20KOD%20(KOD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-KOD-KOD&v=1772576647556 "Company Profit Per Employee (in thousands of dollars) Chart KOD (KOD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Kodiak Sciences (KOD) is a biotech R&D company (focused on eye diseases). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of cash in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772576647619 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Kodiak Sciences (KOD) is a clinical-stage biopharmaceutical company specializing in the treatment of retinal diseases. The company is in the R&D phase and is not commercially profitable. This chart reflects the current investment (loss) in research per employee working on the development of new ophthalmic drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772576647670 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee KOD (KOD)
Kodiak Sciences develops drugs to treat retinal diseases. For a biotech company in clinical trials, this graph represents the point of commercialization. Revenue per employee growth typically results from strategic alliances and advance payments from partners.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-KOD-KOD&v=1772576647741 "Sales chart per company employee KOD (KOD)")
Sales per employee in the market segment - Pharma eyes
Kodiak Sciences (KOD) is a clinical-stage biotech company specializing in the treatment of retinal diseases. They have no approved products or commercial revenue. This graph doesn't reflect their value. Like other R&D biotechs, staff productivity on this graph would be zero. The company is solely focused on the success of clinical trials.
Sales per employee for the market as a whole
Kodiak Sciences is a biotech company specializing in the treatment of retinal diseases. At the R&D stage, this metric is low, as the large research staff generates little revenue. This graph is an indicator of the future: if commercial success occurs, sales will skyrocket, and staff efficiency will soar.
Short shares by company, segment and market as a whole
Shares shorted by company KOD (KOD)
Kodiak Sciences (KOD) is a biopharmaceutical company focused on treating retinal (eye) diseases such as age-related macular degeneration. They are developing longer-acting drugs. This chart shows bearish bets. Bears may be disappointed with clinical trial results or believe the competition is too intense.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-KOD-KOD&v=1772576647928 "Short Shares Chart for the Company KOD (KOD)")
Shares shorted by market segment - Pharma eyes
Kodiak Sciences (KOD) is a biotech company developing anti-VEGF drugs for the treatment of retinal diseases (wet AMD). This chart shows the betting against the biotech sector. The rising betting against the industry reflects investor skepticism following KOD's clinical trial failures and intense competition from market leader Eylea.
Shares shorted by the overall market
Kodiak Sciences (KOD) is a clinical-stage biotech developing drugs for eye diseases. This is a speculative bet on the success of the trials. When this overall pessimism indicator rises, investors are unwilling to take on the binary risk (approval/disapproval). They prefer to sell KOD shares and wait out the panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator KOD (KOD)
Kodiak Sciences is a biotech company focused on eye diseases. Its shares have been extremely volatile following trial failures. This chart above 70 may reflect rare glimmers of hope. Below 30, the stock is often associated with negative R&D news or concerns about the company's future.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-KOD-KOD&v=1772576648149 "RSI 14 indicator chart for the company's stock KOD (KOD)")
RSI 14 Market Segment - Pharma eyes
Kodiak Sciences is a biopharmaceutical company specializing in the treatment of retinal diseases (ophthalmology). Its ABC platform aims to create more durable drugs. This chart shows the overall sentiment in the ophthalmic pharmaceutical sector. It helps understand whether KOD's performance is a reaction to its clinical data or part of a broader trend in this niche.
RSI 14 for the overall market
Kodiak Sciences (KOD) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KOD (KOD)
Kodiak Sciences (KOD) is a clinical-stage biopharmaceutical company specializing in the treatment of retinal diseases (such as age-related macular degeneration). It is developing long-acting treatments. This chart shows the average Wall Street forecast. It reflects analysts' assessments of the clinical data and the company's chances of success against Eylea.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KOD-KOD&v=1772576648544 "A chart showing analyst consensus forecasts for the expected stock price. KOD (KOD)")
The difference between the consensus estimate and the actual stock price KOD (KOD)
Kodiak Sciences is a biotech company focused entirely on treating retinal (eye) diseases. Their goal is to develop drugs that require less frequent administration than existing ones. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in their clinical developments and their potential to change the market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KOD-KOD&v=1772576648697 "A chart showing the difference between the consensus forecast and the actual stock price. KOD (KOD)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Kodiak Sciences (KOD) is a biopharmaceutical company developing long-acting medications for the treatment of age-related retinal degeneration (ARD). The goal is to replace monthly injections. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe R&D can succeed in this highly competitive market.
Analysts' consensus forecast for the overall market share price
Kodiak Sciences (KOD) is a clinical-stage biotech developing long-acting drugs for retinal diseases. This is a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index KOD
Kodiak Sciences is a biotech company focused on the treatment of blindness (age-related macular degeneration, AMD). Their signature product is their antibody-polymer (ABC) platform, which aims to create a drug that requires very few eye injections. This chart is an assessment of their risky R&D bet, reflecting their struggle to prove the superiority of their technology in clinical trials.
AKIMA Market Segment Index - Pharma eyes
Kodiak Sciences (KOD) is a clinical-stage biotech focused on ophthalmology (eyes); the company is developing (after failures) innovative, long-acting drugs for retinal diseases. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this risky R&D bet (KOD) differentiate it from the average pharma company?
The AKIM Index for the overall market
Kodiak Sciences is a biopharmaceutical company developing drugs to treat retinal diseases (AMD, diabetic edema). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this volatile scientific company, which has experienced both setbacks and clinical successes, compares to overall economic trends.
